524742 Share Price Performance
Community Fair Values
- ₹2.51kFV17.5% undervalued intrinsic discount16.58%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative7users have followed this narrative8 days ago author updated this narrative
Recent 524742 News & Updates
No updates
Caplin Point Laboratories Limited Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 07, 2025
- Earnings per share (EPS)
- 70.56
- Gross Margin
- 60.21%
- Net Profit Margin
- 27.68%
- Debt/Equity Ratio
- 0.02%
Caplin Point Laboratories Limited Competitors
About 524742
- Founded
- 1990
- Employees
- 3406
- CEO
- WebsiteView website
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry syrups, lyophilized vials, prefilled syringes, emulsion injection, and topicals. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.
Indian Market Performance
- 7 Days: -1.9%
- 3 Months: 5.0%
- 1 Year: -6.4%
- Year to Date: -0.9%
Over the last 7 days, the market has dropped 1.9%, driven by a loss of 2.7% in the Financials sector. In the last 12 months the market is down 6.4%. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading